Avtor/Urednik		Kodre, Veronika; Černelč, Peter
Naslov		Zdravljenje diseminiranega plazmocitoma z zdravilom bortezomib
Prevedeni naslov		Treatment of multiple myeloma with bortezomib
Tip		članek
Vir		Zdrav Vestn
Vol. in št.		Letnik 77, št. Suppl 1
Leto izdaje		2008
Obseg		str. I-87-92
Jezik		slo
Abstrakt		Background In this retrospective study we evaluated effectiveness and safety of bortezomib, comparing our results with already published clinical studies. Methods Patients received bortezomib as part of everyday clinical practice and in the range of approved indications. We evaluated bortezomib effectiveness in 66 patients according to modified SWOG criteria and treatment responsiveness (CR, VGPR, PR, MR) or unresponsiveness (SD, PD). Treatment responsiveness was compared according to high risk (beta-2 microglobulin >= 5,5 mg/L) or standard risk (beta-2 mikroglobulin < 5.5 mg/L), patient's age (> 65 ali < 65 let), number of previous treatments (1 ali > 1) and previous treatment with thalidomid. Side effects and reasons for early treatment discontinuation were also evaluated. Results Patients received 1‐7 previous treatments (median 1.5). Treatment responsiveness was observed in 80.3% patients (1.5% CR, 45.5 % VGPR, 21.2% PR and 12.1% MR). No statistical significant influence was observed according to: high risk (p = 0.178), age above 65 years (p = 0.756), > 1 previous treatment (p = 0.419) or previous treatment with thalidomid (p = 0.475). Side effects of bortezomib treatment were: anemia (40.9%), peripheral neuropathy grade 3 or more (28.7%), infections (21.2%), herpes zooster (12.1%), neutropenia (10.6%), trombocitopenia (9%) and gastro-intestinal problems (7.5%). Early discontinuation was observed due to: peripheral neuropathy (28.7%), other serious side effects (6%), bortezomib uneffectiveness (19.7%) or planned autologous transplant (15.1%). Conclusions Bortezomib (Velcade) is effective and safe treatment also for patients with multiple myeloma that developed resistance to previous treatments or belong to high risk patient group.
Deskriptorji		MULTIPLE MYELOMA IMMUNOGLOBULINS BETA 2-MICROGLOBULIN BENCE JONES PROTEIN TREATMENT OUTCOME